Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 18, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the SmithKline Beecham Bonus Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event.
- Share Price: GBP 14.59 per share.
- Transaction Type: Increase in interest in Ordinary Shares via dividend re-investment.
- Dividend Date: October 5, 2006.
Material Changes
The filing reports an increase in shareholdings for specific individuals under the SmithKline Beecham Bonus Investment Plan following the re-investment of dividends. No material changes to the company's overall financial position or operations are detailed in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of a director-related transaction in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of shares acquired by Mr. R Bondy and other plan participants, as the specific quantity for Mr. Bondy is listed as "26" but context suggests this may be a partial reference or page number in the source text.
- Confirm the total dividend payout amount for the October 5, 2006 distribution to understand the scale of the re-investment.
- Review the full SmithKline Beecham Bonus Investment Plan rules to understand the mechanics of the share increase.